BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1249 related articles for article (PubMed ID: 16531925)

  • 21. [One stage thyroidectomy and bilateral neck dissection for well-differentiated thyroid carcinoma].
    Pan YF; Zhang XH; Ye GH; Lin BR; Chen XM; Jia XJ; Zhou SM; Wang OC
    Zhonghua Zhong Liu Za Zhi; 2006 May; 28(5):389-92. PubMed ID: 17045009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0.
    Lin JD; Lin KJ; Chao TC; Hseuh C; Tsang NM
    Radiother Oncol; 2008 Oct; 89(1):97-104. PubMed ID: 18534700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Follicular carcinoma and Hürthle cell tumor of the thyroid].
    Miccoli P; Arganini M
    Chir Ital; 1994; 46(4):29-32. PubMed ID: 7882439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
    Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
    J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surgery of thyroid cancer: twelve years' personal experience.
    Pareschi R; Mincione A; Destito D; Mola M; Righini S; Assi A; Dottorini M
    Acta Otorhinolaryngol Ital; 2004 Dec; 24(6):348-53. PubMed ID: 15952685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome.
    Haq M; Harmer C
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):87-93. PubMed ID: 15963067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management and outcome of recurrent well-differentiated thyroid carcinoma.
    Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Differentiated thyroid carcinoma in children and adolescents: therapeutic strategy according to clinic presentation].
    Causeret S; Lifante JC; Borson-Chazot F; Varcus F; Berger N; Peix JL
    Ann Chir; 2004; 129(6-7):359-64. PubMed ID: 15297226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.
    Cappelli C; Pirola I; Braga M; De Martino E; Morassi ML; Gandossi E; Mattanza C; Balzano R; Castellano M; Rosei EA
    Ann Ital Chir; 2006; 77(2):107-13. PubMed ID: 17147082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
    Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
    Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unilateral lobectomy for Hurthle cell adenoma.
    Wasvary H; Czako P; Poulik J; Lucas R
    Am Surg; 1998 Aug; 64(8):729-32; discussion 732-3. PubMed ID: 9697901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Differentiated thyroid carcinoma in childhood].
    Visa Zueras MT; Alonso Blanco M; Yturriaga Matarranz R; Ros Pérez P; Monroy Morante C; Sarriá Oses JM; Barrio Castellanos R
    An Esp Pediatr; 1992 Jul; 37(1):11-4. PubMed ID: 1416515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thyroid cancer in Lebanese children and adolescents: a 15-year experience at a single institution.
    Dardas M; Abboud M; Salti I; Sabri A; Shoucair M; Saleh M; Azar S; Rodriguez-Galindo C; Muwakkit S
    Pediatr Hematol Oncol; 2009 Sep; 26(6):439-47. PubMed ID: 19657994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Management of lymph node metastases in well-differentiated and medullary thyroid cancer: retrospective study on 52 cases].
    Antonelli AR; Piazza C; Lombardi D; Casigli F
    Ann Ital Chir; 2004; 75(3):305-14. PubMed ID: 15605518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
    Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
    J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
    Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
    Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioactive iodine treatment in medullary thyroid carcinoma.
    Faik Erdogan M; Gursoy A; Erdogan G; Kamel N
    Nucl Med Commun; 2006 Apr; 27(4):359-62. PubMed ID: 16531922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hürthle cell tumors: applying molecular markers to define a new management algorithm.
    Maxwell EL; Palme CE; Freeman J
    Arch Otolaryngol Head Neck Surg; 2006 Jan; 132(1):54-8. PubMed ID: 16415430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Small thyroid carcinomas: biological characteristics, diagnosis and therapy].
    Gemsenjäger E; Schweizer I
    Schweiz Med Wochenschr; 1999 May; 129(18):681-90. PubMed ID: 10407941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of total thyroidectomy for differentiated thyroid carcinoma: a 20-year review.
    Ley PB; Roberts JW; Symmonds RE; Hendricks JC; Snyder SK; Frazee RC; Smith RW; McKenney JF; Brindley GV
    Am Surg; 1993 Feb; 59(2):110-4. PubMed ID: 8476139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.